[go: up one dir, main page]

CL2022003289A1 - 2-amino-3-cyanothiophenes annulled and derived for the treatment of cancer - Google Patents

2-amino-3-cyanothiophenes annulled and derived for the treatment of cancer

Info

Publication number
CL2022003289A1
CL2022003289A1 CL2022003289A CL2022003289A CL2022003289A1 CL 2022003289 A1 CL2022003289 A1 CL 2022003289A1 CL 2022003289 A CL2022003289 A CL 2022003289A CL 2022003289 A CL2022003289 A CL 2022003289A CL 2022003289 A1 CL2022003289 A1 CL 2022003289A1
Authority
CL
Chile
Prior art keywords
treatment
cyanothiophenes
annulled
cancer
amino
Prior art date
Application number
CL2022003289A
Other languages
Spanish (es)
Inventor
Treu Matthias
Abbott Jason
Broeker Joachim
Cui Jianwen
W Fesik Stephen
Gollner Andreas
Hodges Tim
Karolyi-Oezguer Jale
Little Andrew
Mantoulidis Andreas
Phan Jason
Sarkar Dhruba
Sun Qi
Waterson Alex
Original Assignee
Boehringer Ingelheim Int
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Univ Vanderbilt filed Critical Boehringer Ingelheim Int
Publication of CL2022003289A1 publication Critical patent/CL2022003289A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención comprende compuestos de la fórmula (I), en donde R1a, R1b, R2a, R2b, Z, R3 a R5, A, p, U, V, W, L y E tienen los significados dados en las reivindicaciones y la memoria descriptiva, su uso como inhibidores de proteínas mutantes de la familia Ras, composiciones farmacéuticas y preparaciones que contienen dichos compuestos y su uso como medicamentos/usos médicos, especialmente como agentes para el tratamiento y/o prevención de enfermedades oncológicas.The present invention comprises compounds of formula (I), wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V, W, L and E have the meanings given in the claims and the specification, their use as inhibitors of mutant proteins of the Ras family, pharmaceutical compositions and preparations containing said compounds and their use as medicaments/medical uses, especially as agents for the treatment and/or prevention of oncological diseases.

CL2022003289A 2020-06-02 2022-11-23 2-amino-3-cyanothiophenes annulled and derived for the treatment of cancer CL2022003289A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063033505P 2020-06-02 2020-06-02
EP20212067 2020-12-05

Publications (1)

Publication Number Publication Date
CL2022003289A1 true CL2022003289A1 (en) 2023-04-14

Family

ID=76269742

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003289A CL2022003289A1 (en) 2020-06-02 2022-11-23 2-amino-3-cyanothiophenes annulled and derived for the treatment of cancer

Country Status (18)

Country Link
US (2) US11945812B2 (en)
EP (2) EP4157837B1 (en)
JP (2) JP7808058B2 (en)
KR (1) KR20230019462A (en)
CN (2) CN116034106B (en)
AU (1) AU2021285032A1 (en)
BR (1) BR112022023462A2 (en)
CA (1) CA3183656A1 (en)
CL (1) CL2022003289A1 (en)
CO (1) CO2022017049A2 (en)
CR (1) CR20220614A (en)
DO (1) DOP2022000266A (en)
EC (1) ECSP22089077A (en)
IL (1) IL298633A (en)
MX (1) MX2022015260A (en)
PE (1) PE20240493A1 (en)
TW (1) TW202210474A (en)
WO (2) WO2021245055A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
SI3849537T1 (en) 2018-09-10 2025-03-31 Mirati Therapeutics, Inc. Combination therapies
KR102871791B1 (en) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. combination therapy
CA3111980A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
WO2020055760A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
MX2021002804A (en) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Combination therapies.
JP7592601B2 (en) 2019-01-10 2024-12-02 ミラティ セラピューティクス， インコーポレイテッド KRAS G12C inhibitors
AU2020337938B2 (en) 2019-08-29 2025-09-25 Array Biopharma Inc. KRas G12D inhibitors
JP2022548791A (en) 2019-09-24 2022-11-21 ミラティ セラピューティクス， インコーポレイテッド combination therapy
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
KR20230019462A (en) 2020-06-02 2023-02-08 베링거 인겔하임 인터내셔날 게엠베하 Cyclic 2-amino-3-cyanothiophene and derivatives for cancer treatment
AU2021340716A1 (en) 2020-09-11 2023-03-30 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
EP4217071A1 (en) 2020-09-23 2023-08-02 Erasca, Inc. Tricyclic pyridones and pyrimidones
US12398154B2 (en) 2020-12-15 2025-08-26 Mirati Therapeutics, Inc. Azaquinazoline pan-KRas inhibitors
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. PAN-KRAS TETRAHYDROPYRIDOPYRIMIDINE INHIBITORS
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
AR125782A1 (en) 2021-05-05 2023-08-16 Revolution Medicines Inc RAS INHIBITORS
AR125787A1 (en) 2021-05-05 2023-08-16 Revolution Medicines Inc RAS INHIBITORS
WO2023099620A1 (en) * 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
JP2024543976A (en) * 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclized 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer - Patents.com
KR20240128852A (en) 2021-12-01 2024-08-27 베링거 인겔하임 인터내셔날 게엠베하 Cyclic 2-amino-3-cyano thiophenes and derivatives for cancer therapy
JP2024543982A (en) * 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Fused 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer - Patents.com
CN118574835A (en) 2021-12-01 2024-08-30 勃林格殷格翰国际有限公司 Cyclic 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer
US20250163039A1 (en) * 2021-12-22 2025-05-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds for the treatment of cancer
WO2023126822A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
IL314812A (en) 2022-02-09 2024-10-01 Quanta Therapeutics Inc KRAS modulators and their uses
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
EP4532494A1 (en) 2022-05-25 2025-04-09 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
CN120504682A (en) 2022-06-10 2025-08-19 锐新医药公司 Macrocyclic RAS inhibitors
WO2023244599A1 (en) * 2022-06-15 2023-12-21 Mirati Therapeutics, Inc. Pan-kras inhibitors
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
KR20250164828A (en) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Composition for inducing RAS GTP hydrolysis and use thereof
CN121263418A (en) 2023-04-07 2026-01-02 锐新医药公司 Macrocyclic RAS inhibitors
KR20260005904A (en) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. macrocyclic RAS inhibitors
CN121100123A (en) 2023-04-14 2025-12-09 锐新医药公司 Crystalline form of Ras inhibitors
TW202448897A (en) 2023-04-14 2024-12-16 美商銳新醫藥公司 Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
TW202508595A (en) 2023-05-04 2025-03-01 美商銳新醫藥公司 Combination therapy for a ras related disease or disorder
WO2024246099A1 (en) * 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2024246114A1 (en) 2023-05-31 2024-12-05 Boehringer Ingelheim International Gmbh Survivin as a biomarker for predicting the responsiveness of cancer treatment
TW202500135A (en) 2023-06-02 2025-01-01 日商第一三共股份有限公司 Combination of anti-her3 antibody-drug conjugate and rasg12c inhibitor
WO2025016899A1 (en) * 2023-07-19 2025-01-23 Bayer Aktiengesellschaft Spirocyclic compounds for the treatment of cancer
TW202510846A (en) 2023-08-02 2025-03-16 美商耐瑞歐醫療公司 Protein tyrosine phosphatase degraders and uses thereof
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025132549A1 (en) 2023-12-20 2025-06-26 Boehringer Ingelheim International Gmbh Cancer combination therapy using zongertinib and a kras g12c inhibitor
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1761528T1 (en) * 2004-06-11 2008-06-30 Japan Tobacco Inc 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO?á2,3-D?åPYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER
CN103396488A (en) 2008-12-12 2013-11-20 贝林格尔.英格海姆国际有限公司 Anti-IGF antibodies
AR090151A1 (en) 2012-03-07 2014-10-22 Lilly Co Eli RAF INHIBITING COMPOUNDS
EA029768B1 (en) * 2012-03-14 2018-05-31 Люпин Лимитед Heterocyclyl compounds
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
KR20160076519A (en) * 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Inhibitors of kras g12c
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
JP6503386B2 (en) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel spiro [3H-indol-3,2'-pyrrolidine] -2 (1H) -one compounds and derivatives as MDM2-p53 inhibitors
KR20170042779A (en) 2014-08-21 2017-04-19 베링거 인겔하임 인터내셔날 게엠베하 New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
PL3359542T3 (en) 2015-10-09 2021-09-20 Boehringer Ingelheim International Gmbh COMPOUNDS AND DERIVATIVES SPIRO [3H-INDOLO-3,2′-PYROLIDINE] -2 (1H) -ONE AS MDM2-P53 INHIBITORS
JP7039489B2 (en) 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド KRAS G12C inhibitor
CA3081983A1 (en) 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
EA201991528A1 (en) 2016-12-22 2020-01-16 Эмджен Инк. Benzisothiazole, isothiazole [3,4-b] pyridine, quinazoline, phthalazine, pyrido [2,3-d] pyridazine and pyrido [2,3-d] pyrimidine derivatives in a red herbal solution COLORECTAL CANCER
US10898487B2 (en) 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
US10647715B2 (en) * 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
MY208632A (en) 2017-12-21 2025-05-21 Boehringer Ingelheim Int Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
CA3097231A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
JP7516029B2 (en) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
EP3930845A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020177629A1 (en) 2019-03-01 2020-09-10 劲方医药科技(上海)有限公司 Spiro-substituted pyrimidine-fused cyclic compound, preparation method therefor and medical use thereof
US20220227738A1 (en) 2019-05-20 2022-07-21 California Institute Of Technology Kras g12c inhibitors and uses thereof
CN114828964B (en) 2019-12-11 2023-11-24 伊莱利利公司 KRAS G12C inhibitors
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
WO2021139748A1 (en) 2020-01-08 2021-07-15 Ascentage Pharma (Suzhou) Co., Ltd. Spirocyclic tetrahydroquinazolines
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
CN113683616B (en) 2020-05-18 2025-12-30 广州百霆医药科技有限公司 KRAS G12C mutant protein inhibitor
KR20230019462A (en) 2020-06-02 2023-02-08 베링거 인겔하임 인터내셔날 게엠베하 Cyclic 2-amino-3-cyanothiophene and derivatives for cancer treatment
US20230227470A1 (en) 2021-12-01 2023-07-20 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP2024543975A (en) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclized 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer - Patents.com
JP2024543982A (en) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Fused 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer - Patents.com
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
JP2024543976A (en) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclized 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer - Patents.com
CN118574835A (en) 2021-12-01 2024-08-30 勃林格殷格翰国际有限公司 Cyclic 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer

Also Published As

Publication number Publication date
JP2023527891A (en) 2023-06-30
IL298633A (en) 2023-01-01
JP2023528623A (en) 2023-07-05
US11945812B2 (en) 2024-04-02
TW202210474A (en) 2022-03-16
CN116234806A (en) 2023-06-06
ECSP22089077A (en) 2022-12-30
DOP2022000266A (en) 2023-01-15
EP4157836B1 (en) 2025-10-29
JP7808056B2 (en) 2026-01-28
CO2022017049A2 (en) 2023-02-06
EP4157837B1 (en) 2024-12-18
WO2021245055A1 (en) 2021-12-09
MX2022015260A (en) 2023-01-11
WO2021245051A1 (en) 2021-12-09
EP4157837A1 (en) 2023-04-05
PE20240493A1 (en) 2024-03-15
CA3183656A1 (en) 2021-12-09
BR112022023462A2 (en) 2022-12-20
AU2021285032A1 (en) 2022-12-08
US20230212164A1 (en) 2023-07-06
US20210380574A1 (en) 2021-12-09
EP4157836A1 (en) 2023-04-05
CN116034106A (en) 2023-04-28
JP7808058B2 (en) 2026-01-28
CN116034106B (en) 2025-11-04
CR20220614A (en) 2023-05-08
US20250002485A1 (en) 2025-01-02
KR20230019462A (en) 2023-02-08

Similar Documents

Publication Publication Date Title
CO2022017049A2 (en) 2-amino-3-cyanothiophenes annulled and derived for the treatment of cancer
DOP2024000101A (en) 2-AMINO-3-CYANO-CANCELLED THIOPHENES AND DERIVATIVES FOR CANCER TREATMENT
CL2021000907A1 (en) New benzylamino-substituted pyridopyrimidinones and derivatives as sos1 inhibitors (divisional application n ° 01501-2020)
AR132802A1 (en) 2-AMINO-3-CYANOTHIOPHENES WITH SPIROCYCLIC RINGS AND DERIVATIVES FOR THE TREATMENT OF CANCER
MX2024001894A (en) Heterocyclic compounds and methods of use.
CO2022015054A2 (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
DOP2022000039A (en) SHP2 PYRAZOLO[3,4-B]PYRAZINE-TYPE PHOSPHATASE INHIBITORS
CL2023001738A1 (en) prmt5 inhibitors
DOP2021000198A (en) COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
MX2019012847A (en) C5-anilinoquinazoline compounds and their use in treating cancer.
ECSP11011113A (en) VEGF-R2 PIRIDYLOXI-INDOLES INHIBITORS AND USE OF THE SAME FOR THE TREATMENT OF DISEASES
MX2022001158A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy.
ECSP23030959A (en) COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
ECSP088561A (en) PIRIMIDINIL-ARIL-UREA DERIVATIVES THAT ARE FGF INHIBITORS
UY38228A (en) TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
BR112022008000A2 (en) PYRAZOLE-HETEROARYL DERIVATIVE, PREPARATION METHOD FOR IT AND MEDICAL USE THEREOF
BR112022000251A2 (en) Macrocyclic Spirocycle Derivatives as mcl-1 Inhibitors
BR112023000212A2 (en) MACROCYCLIC ETHER CONTAINING INDOL DERIVATIVES AS MCL-1 INHIBITORS
UY28356A1 (en) DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATIONS OF THE SAME AND ITS USES
CL2019002480A1 (en) Pyrazole derivatives as bromodomain inhibitors.
CL2024002379A1 (en) Pharmaceutical composition and comprising diphenyldiazole derivatives methods of use
ECSP24050199A (en) 2-AMINO-3-CYANO-CANCELLED THIOPHENES AND DERIVATIVES FOR CANCER TREATMENT
BR112022024117A2 (en) MACROCYCLIC 7-PYRAZOL-5-YL-INDOL DERIVATIVES AS MCL-1 INHIBITORS
BR112022025631A2 (en) N-LINKED MACROCYCLIC 4-(PYRAZOL-5-IL)-INDOLE DERIVATIVES AS MCL-1 INHIBITORS
CL2025002072A1 (en) prmt5-mta inhibitors.